Trial Profile
A randomized, double-blind, multicenter, phase 3 study to compare the efficacy and safety of BMO-2 (adalimumab) and Humira® (adalimumab) in patients with active rheumatoid arthritis - BMO-2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Biocon
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 09 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2017 Planned number of patients changed from 140 to 220.